Phase i clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors

Investigational New Drugs

Volumn 32, Issue 6, 2014, Pages 1188-1196

  Bahleda, Rastislav ^a   Sessa, Cristiana ^b   Del Conte, Gianluca ^c   Gianni, Luca ^c   Capri, Giuseppe ^d   Varga, Andrea ^a   Oprea, Corina ^e   Daglish, Byzance ^e   Hospitel, Marie ^e   Soria, Jean Charles ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e SANOFI   (France)

Author keywords

Chemotherapy; Ombrabulin; Platinum; Taxane; Vascular disrupting agent

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; OMBRABULIN; PACLITAXEL; SERINE; TAXOID;

ADULT; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; DRUG INTERACTION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PHASE 1 CLINICAL TRIAL; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SERINE; TAXOIDS; YOUNG ADULT;

EID: 84938682996     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0119-0     Document Type: Article

References (24)

1. McKeage MJ, Baguley BC (2010) Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 116:1859-1871
2. Nihei Y, Suzuki M, Okano A, Tsuji T, Akiyama Y, Tsuruo T et al (1999) Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 90:1387-1395
3. Hori K, Saito S, Kubota K (2002) A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 86:1604-1614
4. Clemenson C, Jouannot E, Merino-Trigo A, Rubin-Carrez C, Deutsch E (2012) The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models. Invest New Drugs 31:273-284
5. Sessa C, Lorusso P, Tolcher A, Farace F, Lassau N, Delmonte A et al (2013) Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. Clin Cancer Res 19:4832-4842
6. Soria J, Sessa C, Perotti A, Massard C, Armand J, Lassaud N et al. (2008) A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. Proceedings of the American Association for Cancer Research 99th Annual Meeting; Abstract LB-302.
7. Eskens F, Tresca P, Tosi D, Van Doorn L, Fontaine H, Van der Gaast A et al (2014) A phase I dose escalation and pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) combined with docetaxel in advanced solid tumors. Br J Cancer 110:2170-2177
8. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (taxotere): model building and validation. J Pharmacokinet Biopharm 24:153-172
9. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT et al (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196
10. Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA et al (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24:4963-4970
11. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
12. Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I et al (2011) Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29:2965-2971
13. Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F et al (2012) International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 30:2829-2836
14. du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S et al (2010) A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 21:370-375
15. Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J et al (2011) Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 22:2036-2041
16. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
17. Subbiah IM, Lenihan DJ, Tsimberidou AM (2011) Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist 16:1120-1130
18. Felici A, Loos WJ, Verweij J, Cirillo I, de Bruijn P, Nooter K et al (2006) A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. Cancer Chemother Pharmacol 58:673-680
19. Vergote I, Amant F, Oskay-Oezcelik G, Musib L, Michel AL, Darstein C et al (2009) Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study. Int J Gynecol Cancer 19:1505-1510
20. Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K et al (1988) Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 28:208-215
21. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C et al (1989) A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7:651-661
22. Morinaga Y, Suga Y, Ehara S, Harada K, Nihei Y, Suzuki M (2003) Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 94:200-204
23. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA et al (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9:1692-1703
24. Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M et al (2007) Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 97:888-894